GLP-1 Mental Health Screen

Pre-Treatment Mental Health Screening

Placeholder: baseline mood and history are captured before dosing.

• PHQ-9: Screening tool (9-item depression scale)
• 5: Severity bands (minimal to severe)
• Yes/No: History questions (prior psychiatric care)
• Day 0: Baseline window (before first dose)

Why baseline screening matters

Placeholder text: establishes a reference mood score for comparison.

Placeholder: baseline score anchors every later comparison.

Prior psychiatric history intake

Placeholder text: prior diagnoses and treatments are logged briefly.

Risk stratification at intake

Placeholder text: patients are sorted into low, moderate, high risk.

Therapy Start & Check-In Schedule

Placeholder: dosing begins alongside a structured check-in plan.

• 2 wk: First check-in (post first dose)
• ~4 wk: Early phase length (close monitoring)
• Visit/call: Contact method (clinician or nurse line)
• Defined: Escalation path (set at initiation)

Setting the check-in cadence

Placeholder text: early visits are scheduled closer together.

Placeholder: closer spacing catches early symptom shifts.

Patient and caregiver education

Placeholder text: patients learn which symptoms to report.

Documentation of the plan

Placeholder text: schedule and thresholds are recorded in chart.

Ongoing Mood & Depression Rescreening

Placeholder: periodic PHQ-9 rechecks continue across treatment.

• 12 wk: Maintenance interval (once stabilized)
• PHQ-9: Rescreen tool (same scale each time)
• 3-way: Trend tracked (stable/improving/worsening)
• Visit notes: Data source (plus self-report)

Periodic rescreening cadence

Placeholder text: spacing widens once mood looks stable.

Placeholder: consistent rechecks reveal slow drift early.

Comparing against baseline

Placeholder text: each score is compared to the prior checkpoint.

Adjusting monitoring intensity

Placeholder text: risk level shifts how often checks occur.

Recognizing Worsening Symptoms

Placeholder: new or worsening symptoms trigger urgent review.

• PHQ-9 ≥15: Warning threshold (or sharp rise)
• Any report: Suicidal ideation (immediate escalation)
• Same day: Response time (urgent evaluation)
• 2 paths: Branch outcome (continue vs. hold dose)

Signals that trigger review

Placeholder text: mood drop or ideation report flags the case.

Placeholder: any suicidal ideation mention triggers evaluation now.

Immediate evaluation workflow

Placeholder text: clinician reviews and decides on next step.

Dose-hold and referral options

Placeholder text: therapy may pause pending psychiatric input.

Treatment Outcomes at 12 Months

Placeholder: most patients end stable; some need closer care.

• ~85%: Stable/Improved (illustrative split)
• ~10%: Closer follow-up (illustrative split)
• ~5%: Discontinuation (illustrative split)
• 12 mo: Follow-up horizon (simulated timeline)

The majority outcome pathway

Placeholder text: mood stabilizes or improves alongside weight loss.

Placeholder: sustained screening supports the stable-outcome majority.

The closer-follow-up branch

Placeholder text: some patients need tighter psychiatric monitoring.

The discontinuation branch

Placeholder text: a minority stop therapy on clinical grounds.

Illustrative outcome branches at month 12